Abstract 4018: BBT-207 is a broad-spectrum, highly potent, 4th generation EGFR TKI with enhanced activity to both sensitizing and treatment-emergent EGFR mutations including T790M and C797S
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4018
Abstract: Background: EGFR mutation in non-small cell lung cancer (NSCLC) presents a viable therapeutic target for which tyrosine kinase inhibitor (TKI) therapy has shown impressive clinical benefit over the past 20 years. Unfortunately, most patients inevitably… read more here.
Keywords: bbt 207; t790m c797s; generation; activity ... See more keywords